SEC Form 4 · accession 0000885590-17-000017
Bausch Health Companies Inc. · BHC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul Herendeen
Officer — EVP and CFO
Period of report
Mar 14, 2017
Accepted (ET)
Mar 16, 2017 · 5:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885590
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, no par valueF1 | Mar 14, 2017 | P | 24,000 | $10.72 | A | 174,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents volume-weighted average price of purchases of 24,000 shares of common stock (Shares) of Valeant Pharmaceuticals International, Inc. (the Company) at prices ranging from $10.60 to $10.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of Shares purchased by the reporting person at each separate price within the range set forth in this footnote.